Depo -provera: an injectable progestin, medroxyprogesterone acetate available as a deep intramuscular injection(150 mg) or as a subcutaneous injection (104 mg) with typicaluse, the failure rates is 6%

(E). After 1 yr of use, 50% of users develop amenorrhea, which may be an added advantage for teens with heavy menstrual bleeding, dysmenorrhea, anemias, or blood dyscrasias.Although concern has been directed toward the potential for loss in bone mineral density in adolescents,thereby potentially increasingtheir riskfor osteoporosis later in life, subsequent studies have found that bone density is recovered after discontinuation of the method and is considered safe for use in this population.